EP3541360A1 - Méthode fournissant des avantages de soins bucco-dentaires - Google Patents

Méthode fournissant des avantages de soins bucco-dentaires

Info

Publication number
EP3541360A1
EP3541360A1 EP17788088.7A EP17788088A EP3541360A1 EP 3541360 A1 EP3541360 A1 EP 3541360A1 EP 17788088 A EP17788088 A EP 17788088A EP 3541360 A1 EP3541360 A1 EP 3541360A1
Authority
EP
European Patent Office
Prior art keywords
tablet
fluid
oral cavity
tablets
grams
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP17788088.7A
Other languages
German (de)
English (en)
Inventor
Anthony R. Geonnotti
Patricia L. Golas
Helle Wittorff
Heidi Ziegler Bruun
Dorthe Shackinger BOESEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fertin Pharma AS
Johnson and Johnson Consumer Inc
Original Assignee
Fertin Pharma AS
Johnson and Johnson Consumer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/DK2016/050377 external-priority patent/WO2018091048A1/fr
Priority claimed from US15/356,175 external-priority patent/US10543205B2/en
Application filed by Fertin Pharma AS, Johnson and Johnson Consumer Inc filed Critical Fertin Pharma AS
Publication of EP3541360A1 publication Critical patent/EP3541360A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0216—Solid or semisolid forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/345—Alcohols containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses

Definitions

  • Oral cleansing can be difficult or inconvenient at times, depending on the nature of the cleansing and the situation in which the cleansing must occur.
  • Brushing, flossing, cleaning your tongue and gargling using a variety of devices and compositions well-suited for the privacy of one's home are common oral care practices.
  • the devices and compositions used in oral cleansing practices are less convenient to use away from home, where bathroom facilities might be scarce, unavailable or unsanitary.
  • portable flossers can clean teeth on the go, but they are not discreet as well as not enjoyable to use, therefore consumers do not use them compliantly.
  • a mouthspray Like a mouthwash, a mouthspray can provide the consumer with a quick burst of strong breath-freshening action, which might be overwhelming in an extended-consumption product like gum or lozenges.
  • mouthspray s are obtrusive. Spraying a mouthspray typically generates a noise, which undesirably draws the attention of the public to the consumer.
  • mouthsprays are typically packaged in relatively expensive and complex metal canisters, which can clog in use and are not environmentally friendly.
  • misdirecting the spray not only wastes the product, but can result in irritated eyes, a sticky face and/or stained clothing.
  • the tablets of the present invention are chewable, dissolvable tablets.
  • chewable, dissolvable tablets include tablets that can be bitten and chewed by a user and tend to dissolve over time, as opposed to, for example, gums and/or relatively harder solid formats (e.g. lozenges and/or hard candies) which tend to be more difficult to bite (hard solid formats) and/or contain portions that do not dissolve over time for its normal use (gums).
  • the tablets of the present invention may be prepared via any of a variety of tableting methods known in the art.
  • Conventional methods of tablet production include direct compression ("dry blending"), dry granulation followed by compression, wet granulation followed by drying and compression, application of energy to a blend of materials to be tableted, including applying heat, microwave, infrared, and other energies, combinations of two or more thereof, and the like.
  • dry blending dry granulation followed by compression
  • wet granulation followed by drying and compression application of energy to a blend of materials to be tableted, including applying heat, microwave, infrared, and other energies, combinations of two or more thereof, and the like.
  • the tablets comprise one or more sugar alcohols selected from the group consisting of sorbitol, lactitol, xylitol, mannitol, maltitol, isomalt, and combinations two or more thereof.
  • the carbohydrates for use in the present invention may be direct compressible (DC) or non-directly compressible (non-DC).
  • DC and non-DC are readily understood by one of skill in the art.
  • Suppliers of sugar alcohols provide clear guidance to the user as for the ability for use in relation to compression of tablets.
  • a non-DC particle in this connection is referred to as a particle which is not expressly recommended by the supplier for compression.
  • An example of a non-DC grade of erythritol is Zerose erythritol 16952F supplied by Cargill whereas an example of a direct compressible (DC) grade of erythritol includes ZeroseTM DC 16966 also supplied by Cargill.
  • the tablets comprise both DC and non-DC carbohydrates.
  • the tablets comprise non-DC erythritol in combination with one or more DC sugar alcohols.
  • the amount of non-DC erythritol particles is relatively high. It is particularly high when considering that the erythritol in a conventional sense is not regarded attractive for compression, but the mouthfeel and salivation perceived by the user in such methods is improved when compared to low amounts or the same amounts of DC erythritol.
  • the tablets of the present invention comprise a total amount of all carbohydrates in amount of at least 40% by weight of the tablet, including from about 40 to about 99%), from about 60 to 99%, from about 75 to about 95%, from about 80 to about 90%) by weight of the tablets.
  • the carbohydrates comprise one or more sugar alcohols
  • the tablet comprises a total amount of sugar alcohols of at least 40%) by weight of the tablet, including from about 40 to about 99%, from about 60 to 99%), from about 75 to about 95%, from about 80 to about 90% by weight of the tablets.
  • the tablets comprise at least 20% of each of two or more carbohydrates, including at least 20% of xylitol and at least 20% of one or more other sugar alcohols.
  • compositions of the present invention comprise essential oils.
  • Essential oils are volatile aromatic oils which may be synthetic or may be derived from plants by distillation, expression or extraction, and which usually carry the odor or flavor of the plant from which they are obtained.
  • Useful essential oils may provide antiseptic activity. Some of these essential oils also act as flavoring agents.
  • Menthol (CH3C6H9(C3H7)OH), also known as hexahydrothymol) is also only slightly soluble in alcohol, and is fairly volatile. Menthol, in addition to any antiseptic properties, provides a cooling, tingling sensation.
  • Suitable antimicrobial agents include Halogenated Diphenyl Ethers, 2',4,4'- trichloro-2-hydroxy-diphenyl ether (Triclosan), 2,2'-dihydroxy-5,5'-dibromo-diphenyl ether, Halogenated Salicylanilides, 4'5-dibromosalicylanilide, 3,4',5-trichlorosalcylanilide, 3,4',5- tribromosalicylanilide, 2,3,3 ',5-tetrachlorosalicylanilide, 3,3 ',5-tetrachlorosalicylanilide, 3,5, dibromo-3 '-trifluorom ethyl salicylanilide, 5-n-octanoyl-3 '-trifluoromethyl salicylanilide, 3,5- dibromo-4'-trifluorom ethyl salicylanilide, 3, 5 -dibromo-3 '
  • cyclic sesquiterpene alcohols such as farnesol
  • N'-alkyl-L-arginine alkyl ester e.g., Lauroyl Arginine Ethyl Ester
  • salts such as described in U.S. Pat. No. 5,874,068 to Engelman et al., herein incorporated by reference in its entirety
  • Amino acid derivative compounds as described in U.S. Patent Publication No. 20160145203 to Gambogi, et al., herein
  • the tablets for use in the present invention may comprise any of a variety of additional ingredients suitable for use in the tablets including, for example, sweeteners, lubricants, fillers, adsorbents, disintegrants, glidants, superdisintegrants, flavor and aroma agents, antioxidants, preservatives, texture enhancers, coloring agents, and the like, and mixtures of two or more thereof.
  • the tablets may comprise any suitable total amounts of additional sweeteners including from 0.001 to about 8% by weight, including from about 0.02 to about 8%, from about 0.1 to about 3%, from about 0.1 to about 1%, and from about 0.1 to about 0.5% by weight of the tablet.
  • the tablets may also include lubricant materials in certain embodiments.
  • Suitable lubricants include, but are not limited to, long chain fatty acids and their salts, such as magnesium stearate and stearic acid, talc, glycerides waxes, and mixtures thereof.
  • Such materials may be present in any suitable amount including from about 0.01 to about 5%, including from about 0.1 to about 5%, from about 0.5 to about 3%, including from about 0.5 to about 2% by weight of the tablet.
  • flavors and aromatics include, but are not limited to, essential oils including distillations, solvent extractions, or cold expressions of chopped flowers, leaves, peel or pulped whole fruit containing mixtures of alcohols, esters, aldehydes and lactones; essences including either diluted solutions of essential oils, or mixtures of synthetic chemicals blended to match the natural flavor of the fruit (e.g., strawberry, raspberry and black currant); artificial and natural flavors of brews and liquors, e.g., cognac, whisky, rum, gin, sherry, port, and wine; tobacco, coffee, tea, cocoa, and mint; fruit juices including expelled juice from washed, scrubbed fruits such as lemon, orange, and lime; spear mint, pepper mint, wintergreen, cinnamon, cacoe/cocoa, vanilla, liquorice, menthol, eucalyptus, aniseeds nuts (e.g., peanuts, coconuts, hazelnuts, chestnuts, walnuts, colanuts), almonds, raisins; and
  • texture enhancers include, but are not limited to, pectin, polyethylene oxide, and carrageenan, and mixtures thereof. In one embodiment, texture enhancers are used at levels of from about 0.1% to about 10% percent by weight.
  • the tablets may be made by mixing its ingredients and heating them until they melt into a syrup, then exposing the mixture to pressurized carbon dioxide gas (about 600 pounds per square inch, or psi) and allowing it to cool. The process causes tiny high-pressure bubbles to be trapped inside the candy. When the tablet is placed in the mouth and comes into contact with saliva, the tablet breaks and dissolves, releasing the carbon dioxide from the bubbles, resulting in a popping and sizzling sound and leaving a slight tingling sensation.
  • pressurized carbon dioxide gas about 600 pounds per square inch, or psi
  • the tablets of the present invention are not gums and are substantially free of gum bases as used conventionally to manufacture gums, as opposed to chewable, dissolvable tablets.
  • the tablets of the present invention are not sufficiently heated to form hard candies nor lozenges as such terms and their manufacture is understood in the art and which product forms are intended to dissolve more slowly than chewable, dissolvable tablets.
  • the methods of the present invention comprise chewing said tablet to generate a fluid in the oral cavity, preferably chewing said tablet to dissolve, or while dissolving, at least a portion thereof and generate a fluid comprising ingredients from said tablet.
  • the tablet may be chewed for any time sufficient to generate fluid in accord with embodiments comprising a chewing step, including, for example, chewing for at least 5 seconds, including at least 10 seconds, at least 15 seconds, at least 20 seconds, or at least 30 seconds. In certain preferred embodiments, the tablet is chewed for about 10 seconds or for at least 10 seconds.
  • the fluid is forced around the oral cavity using muscular movements of the cheeks and/or tongue. In certain embodiments, the fluid is forced around the oral cavity with the lips closed. In certain preferred embodiments, the forcing step comprises forcing at least a portion of the fluid generated around the mouth, with lips closed, using muscular movements of the cheeks and tongue.
  • the fluid may be forced/moved within the oral cavity for any suitable period of time including at for at least 5 seconds, including at least 10 seconds, at least 15 seconds, at least 20 seconds, or at least 30 seconds. In certain preferred embodiments, the fluid is agitated for about 30 seconds or for at least 30 seconds.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • General Preparation And Processing Of Foods (AREA)

Abstract

L'invention concerne des méthodes fournissant au moins un avantage de soin buccal par l'introduction d'un comprimé dans la cavité buccale pour générer un fluide et forçant au moins une partie du fluide généré autour de la cavité buccale, par exemple, par bain de bouche, rinçage, lavage, etc, pour fournir un avantage de soin buccal.
EP17788088.7A 2016-11-18 2017-10-13 Méthode fournissant des avantages de soins bucco-dentaires Pending EP3541360A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/DK2016/050377 WO2018091048A1 (fr) 2016-11-18 2016-11-18 Véhicule d'administration orale
US15/356,175 US10543205B2 (en) 2016-11-18 2016-11-18 Oral delivery vehicle containing nicotine
PCT/US2017/056554 WO2018093501A1 (fr) 2016-11-18 2017-10-13 Méthode fournissant des avantages de soins bucco-dentaires

Publications (1)

Publication Number Publication Date
EP3541360A1 true EP3541360A1 (fr) 2019-09-25

Family

ID=60083055

Family Applications (2)

Application Number Title Priority Date Filing Date
EP17788088.7A Pending EP3541360A1 (fr) 2016-11-18 2017-10-13 Méthode fournissant des avantages de soins bucco-dentaires
EP17783711.9A Active EP3541359B1 (fr) 2016-11-18 2017-10-13 Comprimé comprenant un liant séparé et de l'érythritol

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP17783711.9A Active EP3541359B1 (fr) 2016-11-18 2017-10-13 Comprimé comprenant un liant séparé et de l'érythritol

Country Status (14)

Country Link
EP (2) EP3541360A1 (fr)
JP (2) JP7297666B2 (fr)
KR (1) KR102582802B1 (fr)
CN (2) CN110087634A (fr)
AU (4) AU2017360584B2 (fr)
BR (2) BR112019010115A8 (fr)
CA (2) CA3044382A1 (fr)
DK (1) DK3541359T3 (fr)
ES (1) ES2860802T3 (fr)
MA (1) MA46822A (fr)
MX (2) MX2019005828A (fr)
PL (1) PL3541359T3 (fr)
RU (1) RU2736072C1 (fr)
WO (2) WO2018093501A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10632076B2 (en) 2016-11-18 2020-04-28 Fertin Pharma A/S Tablet comprising separate binder and erythritol
US10543205B2 (en) 2016-11-18 2020-01-28 Fertin Pharma A/S Oral delivery vehicle containing nicotine
CN112118831B (zh) * 2018-05-17 2023-04-21 费尔廷制药公司 适用于活性药物成分的压片口香糖
US11096894B2 (en) * 2018-05-17 2021-08-24 Fertin Pharma A/S Oral tablet for induced saliva generation
US11058633B2 (en) 2018-05-17 2021-07-13 Fertin Pharma A/S Disintegrating oral tablet suitable for active pharmaceutical ingredients
US11058641B2 (en) 2018-05-17 2021-07-13 Fertin Pharma A/S Oral tablet for taste masking of active ingredients
US20190350858A1 (en) * 2018-05-17 2019-11-21 Fertin Pharma A/S Oral tablet for delivery of active ingredients to the gastrointestinal tract
US11096895B2 (en) * 2018-05-17 2021-08-24 Fertin Pharma A/S Oral tablet suitable for active pharmaceutical ingredients
US11135157B2 (en) 2018-05-17 2021-10-05 Fertin Pharma A/S Oral tablet for delivery of active ingredients to the throat
US11090263B2 (en) 2018-05-22 2021-08-17 Fertin Pharma A/S Tableted chewing gum suitable for active pharmaceutical ingredients
US11052047B2 (en) 2018-05-17 2021-07-06 Fertin Pharma A/S Oral tablet suitable for fast release of active pharmaceutical ingredients
US11096896B2 (en) * 2018-05-17 2021-08-24 Fertin Pharma A/S Tablet dosage form for buccal absorption of active ingredients
US20210106516A1 (en) * 2019-10-11 2021-04-15 Fertin Pharma A/S Ion-Exchange Composition With Water-Soluble Mucoadhesive Polymers
KR102345862B1 (ko) * 2021-03-18 2022-01-03 김현진 팝핑 성분을 포함하는 고체 구강청결용 조성물

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4627977A (en) 1985-09-13 1986-12-09 Colgate-Palmolive Company Anticalculus oral composition
US4820506A (en) 1987-05-01 1989-04-11 Research Foundation, State University Of New York Salivary stimulant
TW469135B (en) * 1995-10-03 2001-12-21 Chugai Pharmaceutical Co Ltd Chewable tablet
EP1380308B1 (fr) * 1996-07-12 2008-07-09 Daiichi Pharmaceutical Co., Ltd. Materiaux moules par compression, à désagrégation rapide, et leur procédé de production
GB9716432D0 (en) * 1997-08-05 1997-10-08 Cerestar Holding Bv Tableting of erythritol
US5874068A (en) 1997-12-08 1999-02-23 Warner-Lambert Company Stabilized antiplaque and antigingivitis oral compositions containing N.sup.α -alkyl-L-arginine alkyl ester salts
WO2000025598A1 (fr) 1998-11-03 2000-05-11 Dandy A/S Esters d'acide gras de saccharose prevus pour augmenter la liberation d'ingredients actifs
US6746697B2 (en) * 2000-12-15 2004-06-08 Phytos, Inc. Composition containing Heliopsis longipes root extract and oral carrier
KR20030081472A (ko) * 2001-03-06 2003-10-17 교와 핫꼬 고교 가부시끼가이샤 구강내 속붕괴성 제제
JP2003125706A (ja) 2001-10-23 2003-05-07 Lion Corp 口中清涼製剤
US20040101494A1 (en) 2002-11-26 2004-05-27 Scott Douglas Craig Chewable solid unit dosage forms and methods for delivery of active agents into occlusal surfaces of teeth
US20040223921A1 (en) 2003-05-07 2004-11-11 Rau Allen H. Oral care tablet
EP1786396A1 (fr) 2004-09-02 2007-05-23 The Procter and Gamble Company Composition de soins buccaux comportant des huiles essentielles
US8435542B2 (en) 2005-03-03 2013-05-07 Takasago International Corp. (Usa) Synergistic salivation agents
JP2006335686A (ja) * 2005-06-02 2006-12-14 Hamari Chemicals Ltd 直打用エリスリトール・ソルビトール混合顆粒の製造方法
CN1709229A (zh) * 2005-06-10 2005-12-21 北京阜康仁生物制药科技有限公司 盐酸美金刚口腔崩解片及其制备方法
US20070077300A1 (en) * 2005-09-30 2007-04-05 Wynn David W Oral compositions containing a salivation inducing agent
CN100446759C (zh) * 2006-10-16 2008-12-31 北京科信必成医药科技发展有限公司 一种天麻素口腔崩解片及其制备方法
JP5766899B2 (ja) * 2007-04-11 2015-08-19 ニプロ株式会社 口腔内崩壊剤及びその製造方法
WO2009007768A1 (fr) 2007-07-06 2009-01-15 Gumlink A/S Comprimé comprenant un polyol
EP2264042B1 (fr) * 2007-07-27 2012-07-18 Cargill, Incorporated Micronisation de polyols
CN102143692A (zh) * 2008-09-04 2011-08-03 卡吉尔公司 赤藓醇的压片
US9591852B2 (en) 2009-11-23 2017-03-14 Mcneil-Ppc, Inc. Biofilm disruptive compositions
US8658139B1 (en) * 2010-02-27 2014-02-25 Squigle, Inc. Prevention and treatment of oral diseases
WO2013125350A1 (fr) * 2012-02-23 2013-08-29 フロイント産業株式会社 Excipient à compression directe permettant de désintégrer oralement un comprimé et procédé de production de celui-ci, et comprimé à désintégration orale
JP6266891B2 (ja) * 2013-03-29 2018-01-24 株式会社ロッテ 口腔内洗浄用組成物
US10357054B2 (en) * 2013-10-16 2019-07-23 R.J. Reynolds Tobacco Company Smokeless tobacco pastille
WO2015158637A1 (fr) 2014-04-17 2015-10-22 Unilever Plc Compositions solides d'hygiène buccale
EP3206671B1 (fr) * 2014-10-16 2024-06-12 Cargill, Incorporated Procédé de préparation d'érythritol directement compressible et utilisations de celui-ci
WO2016077464A1 (fr) 2014-11-11 2016-05-19 Johnson & Johnson Consumer Inc. Dérivés d'acides aminés et leurs utilisations
CN104546807B (zh) * 2015-01-21 2020-09-01 齐鲁制药有限公司 奥氮平口腔速溶膜剂

Also Published As

Publication number Publication date
JP2019535729A (ja) 2019-12-12
EP3541359A1 (fr) 2019-09-25
AU2017360378A1 (en) 2019-06-06
JP2019535732A (ja) 2019-12-12
AU2021200826B2 (en) 2022-02-17
MX2019005928A (es) 2019-11-12
RU2019118433A3 (fr) 2020-12-18
WO2018093501A1 (fr) 2018-05-24
EP3541359B1 (fr) 2021-01-27
MX2019005828A (es) 2019-07-08
CN110087634A (zh) 2019-08-02
BR112019008138A2 (pt) 2019-07-02
CA3040830C (fr) 2021-06-15
JP7297666B2 (ja) 2023-06-26
KR20190086512A (ko) 2019-07-22
JP6840849B2 (ja) 2021-03-10
CN109952092A (zh) 2019-06-28
RU2019118433A (ru) 2020-12-18
ES2860802T3 (es) 2021-10-05
MA46822A (fr) 2019-09-25
AU2021200826A1 (en) 2021-03-04
BR112019010115A8 (pt) 2022-07-26
AU2017360584B2 (en) 2020-12-17
WO2018091050A1 (fr) 2018-05-24
AU2017360584A1 (en) 2019-05-02
CN109952092B (zh) 2022-08-23
CA3040830A1 (fr) 2018-05-24
BR112019010115A2 (pt) 2019-08-20
CA3044382A1 (fr) 2018-05-24
RU2736072C1 (ru) 2020-11-11
KR102582802B1 (ko) 2023-10-06
DK3541359T3 (da) 2021-02-22
AU2023214357A1 (en) 2023-08-31
PL3541359T3 (pl) 2021-05-31

Similar Documents

Publication Publication Date Title
US11351103B2 (en) Method of providing oral care benefits
KR102582802B1 (ko) 구강 케어 효과를 제공하는 방법
RU2388457C2 (ru) Продукт, освежающий дыхание, дезинфицирующий полость рта и содержащий экстракт коры магнолии и поверхностно-активное вещество
RU2398593C2 (ru) Жевательные составы с экстрактом коры магнолии быстрого высвобождения
CN101119704B (zh) 口腔护理除臭组合物
US20030035841A1 (en) Edible film formulations containing maltodextrin
CN102548526B (zh) 洁齿剂组合物
JP2013501782A (ja) 口腔ケア組成物
US20080031831A1 (en) Oral anti-calculus compositions and methods of use thereof
MX2007002561A (es) Composicion que comprende aceites esenciales para el cuidado bucal.
CN103153272A (zh) 包含精油化合物的衍生物的组合物以及在个人护理产品中的用途
CN102573769B (zh) 洁齿剂组合物
CN102046158B (zh) 包含抗氧化剂与厚朴提取物的增强的抗细菌组合的口腔组合物
US20130224125A1 (en) Alcohol-free slightly-alcoholic oral care composition and a process for preparing same
KR101992927B1 (ko) 잇몸질환 예방 및 개선용 치약 조성물
US20070098650A1 (en) Dental formulation
JPWO2005089784A1 (ja) 口腔用組成物
JPH08175947A (ja) 口腔用組成物
RU2783120C2 (ru) Способ обеспечения лечебно-профилактических эффектов ухода за полостью рта
US11857653B2 (en) Method of providing an oral care benefit using a poorly-soluble calcium compound and fluoride
RU2777156C1 (ru) Лечебно-профилактическая композиция для ухода за полостью рта для пациентов с бронхиальной астмой
EP1693085A1 (fr) Un kit de nettoyage des dents par la mastification d'un ensemble de gomme à mâcher
WO2006110183A2 (fr) Preparation dentifrice
WO2023222577A1 (fr) Mélanges antimicrobiens

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190614

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40012536

Country of ref document: HK

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: JOHNSON & JOHNSON CONSUMER INC.

Owner name: FERTIN PHARMA A/S

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: JOHNSON & JOHNSON CONSUMER INC.

Owner name: FERTIN PHARMA A/S